Ruchika Ojha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ruchika Ojha has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Alan Maxwell Bond
School of Chemistry, Monash University, Clayton, Victoria 3800, Australia
10 shared publications - Glen B. Deacon
School of Chemistry, Monash University, Clayton 3800, VIC, Australia
7 shared publications - Peter Courtney Junk
College of Science and Engineering, James Cook University, Townsville, Australia
6 shared publications - Suresh Kumar Bhargava
Centre for Advanced Materials and Industrial Chemistry (CAMIC), RMIT University, Melbourne, VIC 3000, Australia
4 shared publications John Andrews
3 shared publicationsJohn F. Boas
School of Physics and Astronomy, Monash University, Clayton, VIC 3800, Australia
3 shared publications
Latest Publications
- Open Access
Nature-Inspired Gold(I) Complexes as Anticancer Agents: Ligand Design, StructureâActivity Relationships, and Mechanisms
Nature-inspired ligands, including natural product scaffolds and bio-inspired motifs, have emerged as an important source for the development of gold(I) complexes with promising preclinical anticancer activity. This review focuses on structurally characterised gold(I) complexes derived from these ligands, emphasising how ligand structure and gold coordination influence the biological activity. This paper covers the synthesis of nature-inspired gold(I) complexes, alkynyl, N-heterocyclic carbene (NHC), heteroatom-donor, and heterobimetallic complexes, which collectively contribute to enhanced cytotoxicity, stability, and mechanistic diversity. By focusing on these nature-inspired gold(I) complexes, this review provides a concise structureâactivity perspective and outlines future opportunities for rational design in anticancer research.
Open AccessNature-Inspired Gold(I) Complexes as Anticancer Agents: Ligand Design, StructureâActivity Relationships, and Mechanisms
Nature-inspired ligands, including natural product scaffolds and bio-inspired motifs, have emerged as an important source for the development of gold(I) complexes with promising preclinical anticancer activity. This review focuses on structurally characterised gold(I) complexes derived from these ligands, emphasising how ligand structure and gold coordination influence the biological activity. This paper covers the synthesis of nature-inspired gold(I) complexes, alkynyl, N-heterocyclic carbene (NHC), heteroatom-donor, and heterobimetallic complexes, which collectively contribute to enhanced cytotoxicity, stability, and mechanistic diversity. By focusing on these nature-inspired gold(I) complexes, this review provides a concise structureâactivity perspective and outlines future opportunities for rational design in anticancer research.
- Open Access
Auranofin Combination Therapy: A New Frontier in Cancer Treatment
Auranofin, a gold(I)-based compound initially developed for the treatment of rheumatoid arthritis, has emerged as a promising anticancer agent with a multimodal mechanism of action. This review comprehensively examines the therapeutic potential of auranofin in oncology focusing on its ability to synergize with conventional and emerging cancer treatments. Here, we discuss the unique pharmacological properties of auranofin, including thioredoxin reductase inhibition, reactive oxygen species induction, and modulation of key apoptotic pathways. Moreover, this article highlights new recent evidence on its ability to synergize with other cancer treatments such as chemotherapy, immunotherapy, and targeted therapies. Particular emphasis is placed on the role of auranofin in overcoming drug resistance and its potential as an adjuvant in precision medicine. By analyzing both preclinical and clinical data, this review provides critical insights into the repositioning of auranofin as a versatile component in contemporary cancer treatment paradigms, while addressing current challenges and future directions for gold-based therapeutics in oncology.
Open AccessAuranofin Combination Therapy: A New Frontier in Cancer Treatment
Auranofin, a gold(I)-based compound initially developed for the treatment of rheumatoid arthritis, has emerged as a promising anticancer agent with a multimodal mechanism of action. This review comprehensively examines the therapeutic potential of auranofin in oncology focusing on its ability to synergize with conventional and emerging cancer treatments. Here, we discuss the unique pharmacological properties of auranofin, including thioredoxin reductase inhibition, reactive oxygen species induction, and modulation of key apoptotic pathways. Moreover, this article highlights new recent evidence on its ability to synergize with other cancer treatments such as chemotherapy, immunotherapy, and targeted therapies. Particular emphasis is placed on the role of auranofin in overcoming drug resistance and its potential as an adjuvant in precision medicine. By analyzing both preclinical and clinical data, this review provides critical insights into the repositioning of auranofin as a versatile component in contemporary cancer treatment paradigms, while addressing current challenges and future directions for gold-based therapeutics in oncology.
- Open Access
- 21 August 2025
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section C Structural Chemistry
- Vol. 81  (9) , 513-518
Syn- and anti-rotamers of the ortho-stereoisomer [Pt{(o-BrC6F4)N(CH2)2NEt2}Cl(py)]
The crystal structure of the ortho-isomer trans-[N-(2-bromo-3,4,5,6-tetrafluorophenyl)-NâČ,NâČ-diethylethane-1,2-diaminato(1â)]chloridopyridineplatinum(II), [PtBr0.1(C12H14BrF4N2)Cl0.9(C5H5N)][PtBr0.4(C12H14BrF4N2)Cl0.6(C5H5N)] or [Pt{(o-BrC6F4)N(CH2)2NEt2}Cl(py)], 1 o , revealed syn and anti rotamers in a 1:1 ratio in the solid state. 1 o crystallizes in the centrosymmetric space group P 1. The Pt-coordinated Cl ligand exhibits partial occupancy with Br, predominantly in the syn-rotamer. Notably, agostic interactions are observed between the Pt centre and a H atom of one of the ethyl groups. The ortho-isomer 1 o was successfully isolated as a side product from the reaction of [Pt{H2N(CH2)2NEt2}Cl2], Tl2CO3 and C6F5Br. While the para-isomer [Pt{(p-BrC6F4)N(CH2)2NEt2}Cl(py)], 1 p , is the main product, the higher solubility of 1 o facilitates its isolation.
- 21 August 2025
- Published by International Union of Crystallography (IUCr) in Acta Crystallographica Section C Structural Chemistry
- Vol. 81  (9) , 513-518
Open AccessSyn- and anti-rotamers of the ortho-stereoisomer [Pt{(o-BrC6F4)N(CH2)2NEt2}Cl(py)]
The crystal structure of the ortho-isomer trans-[N-(2-bromo-3,4,5,6-tetrafluorophenyl)-NâČ,NâČ-diethylethane-1,2-diaminato(1â)]chloridopyridineplatinum(II), [PtBr0.1(C12H14BrF4N2)Cl0.9(C5H5N)][PtBr0.4(C12H14BrF4N2)Cl0.6(C5H5N)] or [Pt{(o-BrC6F4)N(CH2)2NEt2}Cl(py)], 1 o , revealed syn and anti rotamers in a 1:1 ratio in the solid state. 1 o crystallizes in the centrosymmetric space group P 1. The Pt-coordinated Cl ligand exhibits partial occupancy with Br, predominantly in the syn-rotamer. Notably, agostic interactions are observed between the Pt centre and a H atom of one of the ethyl groups. The ortho-isomer 1 o was successfully isolated as a side product from the reaction of [Pt{H2N(CH2)2NEt2}Cl2], Tl2CO3 and C6F5Br. While the para-isomer [Pt{(p-BrC6F4)N(CH2)2NEt2}Cl(py)], 1 p , is the main product, the higher solubility of 1 o facilitates its isolation.
- Open Access
- 23 May 2025
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 541
Unveiling the anticancer potential of gold-sulfur complexes: Mechanisms, delivery strategies, and clinical progression
- 23 May 2025
- Published by Elsevier in Coordination Chemistry Reviews
- Vol. 541
Open AccessUnveiling the anticancer potential of gold-sulfur complexes: Mechanisms, delivery strategies, and clinical progression
- 20 May 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13  (24) , 7106-7117
Biogenic carbon dots derived from the microwave carbonization of amino acid mixture: cellular biocompatible, biomolecular probes, and live cell imaging agents
Green synthesis of novel carbon nanomaterial using a mixture of amino acids and demonstrated their applications in biosensing and bioimaging.
- 20 May 2025
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 13  (24) , 7106-7117
Biogenic carbon dots derived from the microwave carbonization of amino acid mixture: cellular biocompatible, biomolecular probes, and live cell imaging agents
Green synthesis of novel carbon nanomaterial using a mixture of amino acids and demonstrated their applications in biosensing and bioimaging.
- Open Access
- 12 December 2024
- Published by Elsevier in Journal of Energy Storage
- Vol. 107
Insights into the structure-property relationships of activated carbon derived from phenolic resin for electrochemical storage of green hydrogen using proton battery
- 12 December 2024
- Published by Elsevier in Journal of Energy Storage
- Vol. 107
Open AccessInsights into the structure-property relationships of activated carbon derived from phenolic resin for electrochemical storage of green hydrogen using proton battery
- 30 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 281, 117007
Gold(I) complexes of the type [AuL{ÎșC-2-C6H4P(S)Ph2}] [L = PTA, PPh3, PPh2(C6H4-3-SO3Na) and PPh2(2-py)]: Synthesis, characterisation, crystal structures, and In Vitro and In Vivo anticancer properties
- 30 October 2024
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 281, 117007
Gold(I) complexes of the type [AuL{ÎșC-2-C6H4P(S)Ph2}] [L = PTA, PPh3, PPh2(C6H4-3-SO3Na) and PPh2(2-py)]: Synthesis, characterisation, crystal structures, and In Vitro and In Vivo anticancer properties
- 4 September 2024
- Published by Royal Society of Chemistry (RSC)
- p. 47-73
Carbon quantum dots: promising carbon nanomaterials for organic nanozymes, biological imaging and therapeutic applications
Carbon dots, the organic analogs of quantum dots represent the class of fluorescent nanoparticles derived from carbon sources, which are emerging non-toxic biological imaging agents, carbon-based nanozymes and therapeutic agents. These nanostructured carbon dot materials consist of either graphitic or an amorphous carbon core that is covered by varying functional groups, together making these particles chemically stable, water-dispersible, bio-compatible, photoluminescent and photostable. This chapter begins with a detailed description of these nanostructured carbon materials, their classification based on structure and composition, the origin of their fluorescence, synthetic strategies, and surface modification using various chemical functional groups. This is followed by their application as bio-imaging agents, carbon dots-based nanozymes as well as their therapeutic potential and how strongly they rely upon doping, surface modification, biocompatibility, and the less immunogenic response within the biological system.
- 4 September 2024
- Published by Royal Society of Chemistry (RSC)
- p. 47-73
Carbon quantum dots: promising carbon nanomaterials for organic nanozymes, biological imaging and therapeutic applications
Carbon dots, the organic analogs of quantum dots represent the class of fluorescent nanoparticles derived from carbon sources, which are emerging non-toxic biological imaging agents, carbon-based nanozymes and therapeutic agents. These nanostructured carbon dot materials consist of either graphitic or an amorphous carbon core that is covered by varying functional groups, together making these particles chemically stable, water-dispersible, bio-compatible, photoluminescent and photostable. This chapter begins with a detailed description of these nanostructured carbon materials, their classification based on structure and composition, the origin of their fluorescence, synthetic strategies, and surface modification using various chemical functional groups. This is followed by their application as bio-imaging agents, carbon dots-based nanozymes as well as their therapeutic potential and how strongly they rely upon doping, surface modification, biocompatibility, and the less immunogenic response within the biological system.
- Open Access
- 20 July 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12  (25) , e2300768
Smart Nanozymes for Cancer Therapy: The Next Frontier in Oncology
Nanomaterials that mimic the catalytic activity of natural enzymes in the complex biological environment of the human body are called nanozymes. Recently, nanozyme systems have been reported with diagnostic, imaging, and/or therapeutic capabilities. Smart nanozymes strategically exploit the tumor microenvironment (TME) by the in situ generation of reactive species or by the modulation of the TME itself to result in effective cancer therapy. This topical review focuses on such smart nanozymes for cancer diagnosis, and therapy modalities with enhanced therapeutic effects. The dominant factors that guide the rational design and synthesis of nanozymes for cancer therapy include an understanding of the dynamic TME, structureâactivity relationships, surface chemistry for imparting selectivity, and siteâspecific therapy, and stimulusâresponsive modulation of nanozyme activity. This article presents a comprehensive analysis of the subject including the diverse catalytic mechanisms of different types of nanozyme systems, an overview of the TME, cancer diagnosis, and synergistic cancer therapies. The strategic application of nanozymes in cancer treatment can well be a game changer in future oncology. Moreover, recent developments may pave the way for the deployment of nanozyme therapy into other complex healthcare challenges, such as genetic diseases, immune disorders, and ageing.
- 20 July 2023
- Published by Wiley in Advanced Healthcare Materials
- Vol. 12  (25) , e2300768
Open AccessSmart Nanozymes for Cancer Therapy: The Next Frontier in Oncology
Nanomaterials that mimic the catalytic activity of natural enzymes in the complex biological environment of the human body are called nanozymes. Recently, nanozyme systems have been reported with diagnostic, imaging, and/or therapeutic capabilities. Smart nanozymes strategically exploit the tumor microenvironment (TME) by the in situ generation of reactive species or by the modulation of the TME itself to result in effective cancer therapy. This topical review focuses on such smart nanozymes for cancer diagnosis, and therapy modalities with enhanced therapeutic effects. The dominant factors that guide the rational design and synthesis of nanozymes for cancer therapy include an understanding of the dynamic TME, structureâactivity relationships, surface chemistry for imparting selectivity, and siteâspecific therapy, and stimulusâresponsive modulation of nanozyme activity. This article presents a comprehensive analysis of the subject including the diverse catalytic mechanisms of different types of nanozyme systems, an overview of the TME, cancer diagnosis, and synergistic cancer therapies. The strategic application of nanozymes in cancer treatment can well be a game changer in future oncology. Moreover, recent developments may pave the way for the deployment of nanozyme therapy into other complex healthcare challenges, such as genetic diseases, immune disorders, and ageing.
- 1 August 2022
- Published by Elsevier in Catalysis Today
- Vol. 397-399, 155-164
Electrochemical storage reactions of hydrogen in activated carbon from phenolic resin
- 1 August 2022
- Published by Elsevier in Catalysis Today
- Vol. 397-399, 155-164
Electrochemical storage reactions of hydrogen in activated carbon from phenolic resin